Scientific article
Open access

The B-cell response to a primary and booster course of MenACWY-CRM₁₉₇ vaccine administered at 2, 4 and 12 months of age

Published inVaccine, vol. 31, no. 20, p. 2441-2448
Publication date2013

A quadrivalent meningococcal vaccine conjugated to CRM197 (MenACWY-CRM197) is immunogenic in young infants. We assessed the memory B-cell and antibody responses after a primary and booster course of MenACWY-CRM197 in children. At 5 months of age, following primary immunisation, serogroup-specific memory B-cells were detectable in fewer than 25% of children, although protective antibody titres (hSBA ≥ 4) were detectable in 69% of children against serogroup A and more than 95% against the other serogroups. At 12 months, before booster immunisation the percentages with hSBA ≥ 4 were 5% for serogroup A, and between 44 and 70% for the other serogroups. One month after booster immunisation with MenACWY-CRM197 over 50% of children had detectable memory B-cells, and 91% had hSBA ≥ 4 against serogroup A and more than 99% against the other serogroups. These data show that few antigen-specific anticapsular memory B-cells can be detected after two-doses priming with MenACWY-CRM197. For MenC and CRM197, the antigens with the highest number of B-cells at 5 months, there was a definite (p ≤0 .02) but weak correlation with antibody persistence at 12 months. Although previous studies suggest that measuring memory B-cell responses after priming immunisations in infancy can be used to predict antibody persistence and memory responses, this may not be suitable for all antigens in young children.

  • Antibodies, Bacterial/immunology
  • B-Lymphocytes/immunology
  • Bacterial Proteins/administration & dosage/immunology
  • Child
  • Female
  • Humans
  • Immunization, Secondary
  • Immunologic Memory/immunology
  • Infant
  • Meningococcal Vaccines/administration & dosage/immunology
  • Vaccination
  • Vaccines, Conjugate/administration & dosage/immunology
Citation (ISO format)
BLANCHARD ROHNER, Géraldine et al. The B-cell response to a primary and booster course of MenACWY-CRM₁₉₇ vaccine administered at 2, 4 and 12 months of age. In: Vaccine, 2013, vol. 31, n° 20, p. 2441–2448. doi: 10.1016/j.vaccine.2013.03.036
Main files (1)
Article (Published version)
ISSN of the journal0264-410X

Technical informations

Creation02/02/2021 1:32:00 PM
First validation02/02/2021 1:32:00 PM
Update time03/16/2023 12:02:14 AM
Status update03/16/2023 12:02:13 AM
Last indexation01/17/2024 12:25:27 PM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack